⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL126712 | 0.79 | — | — | |
| SCHEMBL10439985 | 0.78 | TSHR (0.43) | — | |
| SCHEMBL11713725 | 0.77 | — | — | |
| SCHEMBL5474745 | 0.77 | — | — | |
| SCHEMBL9509335 | 0.77 | — | — | |
| SCHEMBL29053744 | 0.77 | MMP1 (0.48) | — | |
| SCHEMBL2100144 | 0.75 | — | — | |
| SCHEMBL20599618 | 0.75 | — | — | |
| SCHEMBL20599585 | 0.75 | — | — | |
| SCHEMBL6865020 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100453530-C | Compound for inhibiting VCAM-1 expression and pharmaceutical composition thereof | ATHEROGENICS INC (US) | 2009-01-21 | — | — | CN | claimed |
| CN-101284808-A | Compounds and methods for the inhibition of the expression of VCAM-1 | ATHEROGENICS INC (US) | 2008-10-15 | — | — | CN | claimed |
| US-20080214660-A1 | Compounds and Methods for the Inhibition of the Expression of VCAM-1 | CRABTREE ACQUISITION CO, LLC | 2008-09-04 | — | — | US | claimed |
| EP-1726582-A2 | Compounds and methods for the inhibition of the expression of vcam-1 | Atherogenics, Inc. (US) | 2006-11-29 | — | — | EP | claimed |
| EP-1695959-A1 | Compouds and methods for the inhibition of the expression of VCAM-1 | Atherogenics, Inc. (US) | 2006-08-30 | — | — | EP | claimed |
| US-20020177717-A1 | Compounds and methods for the inhibition of the expression of VCAM-1 | CRABTREE ACQUISITION CO, LLC | 2002-11-28 | — | — | US | claimed |
| CN-1263522-A | Compounds and methods for inhibiting VCAM-1 expression | ATHEROGENICS INC (US) | 2000-08-16 | — | — | CN | claimed |
| EP-0994853-A2 | COMPOUNDS AND METHODS FOR THE INHIBITION OF THE EXPRESSION OF VCAM-1 | Atherogenics, Inc. (US) | 2000-04-26 | — | — | EP | claimed |
| WO-1998051662-A2 | COMPOUNDS AND METHODS FOR THE INHIBITION OF THE EXPRESSION OF VCAM-1 | ATHEROGENICS, INC. (US) | 1998-11-19 | — | — | WO | claimed |
| CN-112955115-B | Bioenergy glyceryl nicotinate, compositions and methods of using the same | 联合利华知识产权控股有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20120295973-A1 | METHODS AND COMPOSITIONS OF DERIVATIVES OF PROBUCOL FOR THE TREATMENT OF DIABETES | SALUTRIA PHARMACEUTICALS LLC | 2012-11-22 | — | — | US | disclosed |
| US-8252840-B2 | administering monoesters of probucol, such as AGI-1067, succinobucol | SALUTRIA PHARMACEUTICALS LLC (US) | 2012-08-28 | — | — | US | disclosed |
| CN-101686676-A | Methods and compositions of derivatives of probucol for the treatment of diabetes | ATHEROGENICS INC | 2010-03-31 | — | — | CN | disclosed |
| EP-2139320-A1 | METHODS AND COMPOSITIONS OF DERIVATIVES OF PROBUCOL FOR THE TREATMENT OF DIABETES | Salutria Pharmaceuticals, LLC (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-0994853-A2 | COMPOUNDS AND METHODS FOR THE INHIBITION OF THE EXPRESSION OF VCAM-1 | Atherogenics, Inc. (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1998051662-A2 | COMPOUNDS AND METHODS FOR THE INHIBITION OF THE EXPRESSION OF VCAM-1 | ATHEROGENICS, INC. (US) | 1998-11-19 | — | — | WO | disclosed |
| US-4801601-A | ANTILEUKEMIA AGENT | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1989-01-31 | — | — | US | disclosed |
| EP-0056962-B1 | N-SUBSTITUTED POLYGLYCIDYL URAZOL COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Henkel Kommanditgesellschaft auf Aktien (DE) | 1985-10-02 | — | — | EP | disclosed |
| US-4393060-A | ANTICANCER | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1983-07-12 | — | — | US | disclosed |
| EP-0056962-A2 | N-substituted polyglycidyl urazol compounds, process for their preparation and pharmaceutical compositions containing them | Henkel Kommanditgesellschaft auf Aktien (DE) | 1982-08-04 | — | — | EP | disclosed |